PRGF® endoret injections for temporomandibular joint osteoarthritis treatment: a one-year follow-up

M. Giacomello, C. Mortellaro, C. Viganoni, A. Crimella, J. Fossati, D. Lauritano

Article ID: 6821
Vol 33, Issue 6S2, 2019
DOI: https://doi.org/10.54517/jbrha6821
Received: 8 January 2020; Accepted: 8 January 2020; Available online: 8 January 2020; Issue release: 8 January 2020

Abstract

This clinical trial investigates the efficacy of PRGF-Endoret® injections for the treatment of temporomandibular joint osteoarthritis by providing patient evaluations at a one-year follow-up. Fifty-two patients with a diagnosis of osteoarthritis according to the American Society of Temporomandibular Joint Surgeons guidelines underwent a cycle of 3 injections (1 per month) of platelet-derived growth factors (PRFG). Two clinical parameters, pain at rest and maximum non-assisted mouth opening, were assessed by the same blinded operator at the time of the diagnosis (baseline), at each appointment during the treatment and at a 1-year follow-up visit. Both the parameters showed improvements that were maintained over time. Statistical analyses evidenced significant changes within the first two injections. Data from the present investigation support findings from studies on other joints, which show the efficacy of PRGF-Endoret injections to reduce symptoms of osteoarthritis and to maintain improvements over time.


Keywords

temporomandibular joint;osteoarthritis;platelet rich plasma;growth factors;injections


References

Supporting Agencies



Copyright (c) 2019 M. Giacomello, C. Mortellaro, C. Viganoni, A. Crimella, J. Fossati, D. Lauritano




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).